Similarly, the use of PPARγ antagonists or genetic knockdown of FABP1/CD36 has been shown to ameliorate MASLD [22, 23, 24, 25]. The gene discussed is PPARG; the disease is metabolic dysfunction-associated steatotic liver disease.